江苏龙网

  1. 首页 > 生活 > >

医学界肿瘤频道|“ASCO”拍了拍“手机对面的你”，2020 POST-ASCO云峰会乘风破浪而来( 二 )


[1]Cortes J, Sch?ffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: emerging data and clinical implications. Cancer Treat Rev. 2018 Nov;70:190–8.
[2] Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015 Jun;21(11):2445–52.[3] Minetta C. Liu, et al. ASCO 2020; abstract 1016.[4] Goel S, Mita AC, Mita M, et al. A Phase I study of eribulin mesylate(E7389), a mechanistically novel inhibitor of microtubule dynamics,in patients with advanced solid tumors. Clin Cancer Res 2009;15: 4207–12.[5]Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulinmesylate (E7389) administered once every 21 days in patients withadvanced solid tumors. Clin Cancer Res 2009; 15: 4213–18.[6] Synold TW, Morgan RJ, Newman EM, et al. A phase Ipharmacokinetic and target validation study of the novelanti-tubulin agent E7389: a California Cancer consortium trial.J Clin Oncol 2005; 23 (16s part I of II): 200s, abstr 3036.[7]Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulinmesylate, a halichondrin B analog, in patients with metastaticbreast cancer previously treated with an anthracycline and a taxane.J Clin Oncol 2009; 27: 2954–61.[8] Cortes J, Vahdat L, Blum JL, et al. Phase II study of thehalichondrin B analog eribulin mesylate in patients with locallyadvanced or metastatic breast cancer previously treated with ananthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28: 3922–28.[9]Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al.; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar;377(9769):914–23.[10] Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594-601. doi:10.1200/JCO.2013.52.4892[11]Twelves C, Awada A, Cortes J, et al. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer (Auckl). 2016;10:77-84. Published 2016 Jun 28. doi:10.4137/BCBCR.S39615[12] Pivot X, Im SA, Guo M, Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370-374. doi:10.1007/s12282-017-0826-4[13] 中国抗癌协会乳腺癌专业委员会. Chinese expert consensus on the clinical diagnosis and treatment of advanced breast carcinoma (2018)%中国晚期乳腺癌临床诊疗专家共识( 2018版)[J]. 中华肿瘤杂志, 2018, 040(009):703-713.[14] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-679. DOI:10.19401/j.cnki.1007-3639.2019.08.009.[15] Inoue K, Ninomiya J, Saito T, et al. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial [published correction appears in Invest New Drugs. 2019 Apr 25;:]. Invest New Drugs. 2019;37(3):538-547. doi:10.1007/s10637-019-00755-x[16]Yonemori K, Shimomura A, Yasojima H, et al. A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. Eur J Cancer. 2019;109:84-91. doi:10.1016/j.ejca.2018.11.014[17]Sch?ffski P, Ray-Coquard IL, Cioff A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–1052.[18] Kawai A, Araki N, Naito Y, et al. Phase 2 study of eribulin in patientswith previously treated advanced or metastatic soft tissue sarcoma. JpnJ Clin Oncol. 2016;47(2):137–144.[19] Sch?ffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazinein previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet.2016;387:1629–1637.[20]Fujisawa Y, Fujimura T, Matsushita S, et al. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study [published online ahead of print, 2020 Mar 20]. Br J Dermatol. 2020;10.1111/bjd.19042. doi:10.1111/bjd.19042[21] Tom Wei-Wu Chen, et al. J Clin Oncol 38: 2020 (suppl; abstr 11507)[22]Michael Nathenson,et al.J Clin Oncol 38:2020(suppl:abstr11559)[23]Pedersini R, di Mauro P, Amoroso V, et al. Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data [published online ahead of print, 2020 Apr[24]https://clinicaltrials.gov/ct2/resultscond=&term=+eribulin&cntry=&state=&city=&dist=


推荐阅读


上一篇：中老年视界|老年人饮食的十大误区

下一篇：百多福养生|夏季是高血压高危季？做好4点能安全度过夏季